CXCL9 and digestive system neoplasm: The current research on gastrointestinal tumors has further validated the critical role of the IFN-γ/STAT1/JAK/CXCL chemokine pathway—particularly involving CXCL9 and CXCL10—in promoting antitumor immune responses.